VALNEVA Initiates Phase I Clinical Study to Evaluate Its Single-Shot Vaccine Candidate against Chikungunya

World News: . []

Lyon France March 13 2018 - Valneva SE a fully integrated commercial stage biotech company focused on developing innovative lifesaving vaccines, today announced the initiation of a Phase I clinical trial in the US to evaluate the safety and immunog...

More news and information about VALNEVA

Published By:

Globe Newswire: 16:46 GMT Tuesday 13th March 2018

Published: .

Search for other references to "valneva" on SPi News


Previous StoryNext Story

SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2018. [Admin Only]
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 0751938.
Privacy Policy | Terms and Conditions | Contact Us